Literature DB >> 17172472

HIV-1 reverse transcriptase plus-strand initiation exhibits preferential sensitivity to non-nucleoside reverse transcriptase inhibitors in vitro.

Jay A Grobler1, Geetha Dornadula, Michele R Rice, Amy L Simcoe, Daria J Hazuda, Michael D Miller.   

Abstract

Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are highly specific and potent allosteric inhibitors of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase. NNRTIs inhibit reverse transcription in a substrate length-dependent manner in biochemical assays and in cell-based HIV-1 replication assays, suggesting a stochastic inhibitory mechanism. Surprisingly, we observed that NNRTIs potently inhibited plus-strand initiation in vitro under conditions in which little or no inhibition of minus-strand DNA synthesis was observed. In assays that recapitulated the initiation of plus-strand DNA synthesis, greater inhibition was observed with an RNA PPT primer than with a DNA primer of corresponding sequence and with wild-type reverse transcriptase but not with NNRTI-resistant enzymes. Structural elements that dictate sensitivity to NNRTIs were revealed using modified plus-strand initiation substrates. The data presented here suggest that specific inhibition of plus-strand initiation may be an important mechanism by which NNRTIs block HIV-1 replication.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17172472     DOI: 10.1074/jbc.M608274200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  25 in total

1.  N348I in HIV-1 reverse transcriptase can counteract the nevirapine-mediated bias toward RNase H cleavage during plus-strand initiation.

Authors:  Mia J Biondi; Greg L Beilhartz; Suzanne McCormick; Matthias Götte
Journal:  J Biol Chem       Date:  2010-06-08       Impact factor: 5.157

Review 2.  Emerging reverse transcriptase inhibitors for HIV-1 infection.

Authors:  Mohammad A Rai; Sam Pannek; Carl J Fichtenbaum
Journal:  Expert Opin Emerg Drugs       Date:  2018-05-10       Impact factor: 4.191

3.  Efavirenz binding site in HIV-1 reverse transcriptase monomers.

Authors:  Valerie A Braz; Mary D Barkley; Rebecca A Jockusch; Patrick L Wintrode
Journal:  Biochemistry       Date:  2010-11-19       Impact factor: 3.162

4.  Timing of the components of the HIV life cycle in productively infected CD4+ T cells in a population of HIV-infected individuals.

Authors:  John M Murray; Anthony D Kelleher; David A Cooper
Journal:  J Virol       Date:  2011-08-10       Impact factor: 5.103

5.  Impact of primer-induced conformational dynamics of HIV-1 reverse transcriptase on polymerase translocation and inhibition.

Authors:  Anick Auger; Greg L Beilhartz; Siqi Zhu; Elizabeth Cauchon; Jean-Pierre Falgueyret; Jay A Grobler; Maryam Ehteshami; Matthias Götte; Roman A Melnyk
Journal:  J Biol Chem       Date:  2011-07-07       Impact factor: 5.157

Review 6.  Human immunodeficiency virus reverse transcriptase: 25 years of research, drug discovery, and promise.

Authors:  Stuart F J Le Grice
Journal:  J Biol Chem       Date:  2012-10-05       Impact factor: 5.157

Review 7.  Retroviral reverse transcriptases.

Authors:  Alon Herschhorn; Amnon Hizi
Journal:  Cell Mol Life Sci       Date:  2010-04-01       Impact factor: 9.261

8.  A cell-based strategy to assess intrinsic inhibition efficiencies of HIV-1 reverse transcriptase inhibitors.

Authors:  Michael E Abram; Manuel Tsiang; Kirsten L White; Christian Callebaut; Michael D Miller
Journal:  Antimicrob Agents Chemother       Date:  2014-11-17       Impact factor: 5.191

9.  A novel molecular mechanism of dual resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors.

Authors:  Galina N Nikolenko; Krista A Delviks-Frankenberry; Vinay K Pathak
Journal:  J Virol       Date:  2010-03-10       Impact factor: 5.103

10.  The triple combination of tenofovir, emtricitabine and efavirenz shows synergistic anti-HIV-1 activity in vitro: a mechanism of action study.

Authors:  Joy Y Feng; John K Ly; Florence Myrick; Derrick Goodman; Kirsten L White; Evguenia S Svarovskaia; Katyna Borroto-Esoda; Michael D Miller
Journal:  Retrovirology       Date:  2009-05-13       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.